Harvard Bioscience appoints John Duke as CEO; Q2 revenue anticipated at $20.4M

HARVARD BIOSCIENCE INC

Jim Green resigns as President & CEO effective July 28, 2025; retirement not due to any disagreement.
John Duke (current board member) appointed CEO effective July 28; base salary $480K, 500k RSU grant.
Rob Gagnon and Seth Benson appointed to Board; Gagnon to chair Audit and Compensation committees.
Preliminary Q2 2025 revenue of $20.4 million; gross margin guidance reiterated at 55%-57%.
Full Q2 2025 financial results expected to be reported on August 11, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.